1. JAK inhibitors did not significantly increase overall cancer incidence in patients with RA compared with other biologics.
2. There is an elevated risk of developing keratinocyte cancer, especially basal cell carcinoma.
3. The addition of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may offer cardiovascular benefits.
4. Further research is needed to confirm the potential cardiovascular benefits of GLP-1 RAs.
5. The findings support the need for continued dermatologic monitoring among JAKi users, particularly those with a history of skin cancer.
6. A subgroup analysis indicated no statistically significant differences in cancer incidence among patients with RA aged 50 years and older with at least one cardiovascular risk factor.

Source: EULAR